Takeda Sees Strong Fundamentals Despite Post-Shire Loss Outlook
Post-Shire Takeda expects losses in its first annual forecast for the combined business, plus "significant headwinds" from expected Velcade erosion. But underlying new and legacy Takeda business is seen remaining strong.
You may also be interested in...
A sizeable group of key late-stage products have the potential to reach the US market in 2020, according to a recent report from Informa’s Biomedtracker. Pharmaceutical and biotech executives will have to be on their A-game to integrate the new wave of products into patient-centric and market access-friendly commercial strategies.
As widely anticipated, Takeda has reached an agreement to divest an ex-Shire ophthalmology drug, as it streamlines the combined post-acquisition business to focus on core therapeutic pillars.
Japanese firm again links with an earlier venture capital partner and some familiar faces to progress its norovirus vaccine outside Japan.